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Highlights 
 Tunicamycin and Brefeldin A, induce ER retention of FLT3-ITD. 
 ER retention of FLT3-ITD results in post-translational modification of p22phox and NOX4. 
 NOX-generated ROS contribute to total pro-survival ROS in AML. 
 AKT pathway is vital for FLT3-ITD at the plasma membrane oncogenic effects. 
 
 
Abstract 
Internal tandem duplication of the juxtamembrane domain of FMS-like tyrosine kinase 3 (FLT3-ITD) 
receptor is the most prevalent FLT3 mutation accounting for 20% of acute myeloid leukemia (AML) 
patients. FLT3-ITD mutation results in ligand-independent constitutive activation of the receptor at the 
plasma membrane and ‘impaired trafficking’ of the receptor in compartments of the endomembrane 
system, such as the endoplasmic reticulum (ER). FLT3-ITD expressing cells have been shown to 
generate increased levels of reactive oxygen species (ROS), in particular NADPH oxidase (NOX)-
generated ROS which act as pro-survival signals. The purpose of this study is to investigate FLT3-ITD 
production of ROS at the plasma membrane and ER in the FLT3-ITD expressing AML cell line MV4-
11. Receptor trafficking inhibitors; Tunicamycin and Brefeldin A induce ER retention of FLT3-ITD, 
resulting in a decrease in protein expression of NOX4 and its partner protein p22phox, thus demonstrating 
the critical importance of FLT3-ITD localization for the generation of pro-survival ROS. NOX-
generated ROS contribute to total endogenous hydrogen peroxide (H2O2) in AML as quantified by flow 
cytometry using the cell-permeable H2O2-probe Peroxy Orange 1 (PO1). We found that PI3K/AKT 
signaling only occurs when FLT3-ITD is expressed at the plasma membrane and is required for the 
production of NOX-generated ROS. ER retention of FLT3-ITD resulted in NOX4 deglycosylation and 
p22phox protein degradation.  
The abbreviations used are : FLT3, FMS-like tyrosine kinase 3 receptor; FLT3-ITD, FLT3-internal 
tandem duplication; FLT3-WT, FLT3- wild type; NOX, NADPH oxidase; p22phox, p22 phagocyte 
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oxidase; ROS, reactive oxygen species; AML, acute myeloid leukemia; ER, endoplasmic reticulum; 
H2O2, hydrogen peroxide; PO1, peroxy orange 1; RTK, receptor tyrosine kinase; COX, 
cyclooxygenase; DUOX, dual oxidase; DMSO, dimethylsulfoxide. 
Keywords:  
 
Acute myeloid leukemia, FLT3-ITD, oncogene, NADPH oxidase, p22phox, pro-survival reactive oxygen 
species. 
 
 
1. Introduction 
Constitutively active mutations in receptor tyrosine kinases (RTKs) are frequently observed in human 
cancers (1, 2). FMS-like tyrosine kinase 3 (FLT3) is a type III RTK expressed in approximately 90% 
of acute myeloid leukemia (AML) cases and regulates early steps of hematopoiesis (3, 4). Internal 
tandem duplication (ITD) of the juxtamembrane domain is the most prevalent mutation of FLT3 present 
in 20% of AML patients, resulting in ligand-independent constitutive activation of the receptor at the 
plasma membrane and impaired trafficking of the receptor in compartments of the biosynthetic route, 
such as the endoplasmic reticulum (ER) (4-8). AML patients with FLT3-ITD mutation have a poor 
prognosis (9, 10). Ligand-independent constitutive activation of FLT3 stimulates autophosphorylation 
of the receptor and downstream signaling pathways including PI3K/AKT, ERK and STAT5 resulting 
in abnormal cell growth, resistance to apoptosis and differentiation block (11-14). Our group 
demonstrated that cells expressing FLT3-ITD produce higher levels of pro-survival reactive oxygen 
species (ROS) in comparison to FLT3-wild type (15-18). 
Increased production of ROS has been linked to various pathophysiological states including leukemia 
(19). Little is known about how FLT3-ITD generates such a stress. NADPH oxidases (NOXs) are one 
of the known sources of ROS in FLT3-ITD expressing cells (18). There are seven NOX isoforms 
NOX1-5 and dual oxidase 1-2 (DUOX1-2), varying in structure, subcellular localization, biochemical 
characteristics and regulatory subunit requirements (p22phox, p47phox, p67phox and Rac1/2). NOX1-4 
require p22phox to produce functionally active NOX (20, 21). NOX2 and NOX4 have been shown 
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previously to be expressed in leukemia (22, 23). Other sources of ROS include mitochondrial ROS, 
cyclooxygenase (COX), xanthine oxidase, cytochrome p450 enzymes and lipooxygenases (24-26). 
Previous studies have looked at the molecular mechanisms through which FLT3-ITD initiates aberrant 
signaling of pro-survival pathways (PI3K, ERK, STAT5) at the plasma membrane and ER FLT3 using 
receptor trafficking inhibitors, Tunicamycin and Brefeldin A (27). However, the molecular mechanism 
describing how mislocalized activation of FLT3-ITD and the aberrant signaling of these downstream 
pathways leads to the production of ROS and sources of ROS remains unknown. To analyze the role of 
the cellular localization of FLT3-ITD in the generation of ROS and their signaling outcomes we utilized 
a panel of inhibitors of ROS production, pro-survival pathways, FLT3-ITD and the 20S proteasome 
alongside ROS specific antibodies and probes. Experiments were carried out in the FLT3-ITD AML 
expressing MV4-11 cell line. 
Receptor trafficking inhibitors, Tunicamycin and Brefeldin A, induce ER retention of FLT3-ITD, 
resulting in a decrease in protein expression of NOX4 and its partner protein p22phox as a result of NOX4 
deglycosylation and p22phox protein degradation. This demonstrates the critical importance of FLT3-
ITD localization for the generation of pro-survival ROS. Finally, we found that PI3K/AKT signaling 
only occurs when FLT3-ITD is expressed at the plasma membrane. 
2. Materials and Methods 
2.1. Cell culture and treatments- The human leukemic cell line MV4-11 (homozygous for the FLT3-
ITD mutation) was purchased from DSMZ (Braunschweig, Germany) (DSMZ no.: ACC 102). The cell 
line was maintained in RPMI-1640 medium supplemented with 10% FBS, 2 mM L-glutamine and 1% 
penicillin/streptomycin in a humidified incubator at 37°C with 5% CO2. 
Tunicamycin (5 µg/ml; Sigma) and Brefeldin A (10 µg/ml; Sigma) induced ER retention of FLT3-ITD 
overnight.  FLT3-ITD was inhibited using PKC412 (50 nM, 200 nM and 250 nM; Tocris) for up to 24 
hours. Cyclooxygenase inhibition was achieved using Diclofenac (Sigma) for 2 hours at indicated 
concentrations. Mitochondrial ROS inhibition was achieved using Rotenone (Tocris) for 1 hour at 
indicated concentrations. Inhibition of AKT was via LY294002 (50 µM; Cell Signaling) overnight. 
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GSK3β inhibition was via SB216763 (5 µM; Tocris) overnight. Inhibition of the 20S proteasome was 
via Lactacystin (5 µM; Merck Millipore) overnight. Dimethylsulfoxide (DMSO) and Ethanol (Brefeldin 
A) were used as vehicle controls. 
2.2. Antibodies- Primary antibodies used for immunoblotting and immunofluorescence included AKT 
(#9272), phospho-AKT (Ser 473; #9271), GSK3β (#9315), phospho-GSK3β (Ser9; #9336, all from Cell 
Signaling Technology), Flt-3 (#SC480), p22phox (#SC20781; both from Santa Cruz Biotechnology), 
NOX4 (#NB110-58849; Novus Biologicals), KDEL (ab12223; Abcam) and β-Actin (#A5441; Sigma). 
Microscopy- Mounted slides were viewed on a Leica DM LB2 microscope with Nikon Digital Sight 
DS-U2 camera, using 40x and 100x objectives. Images were taken using the software NIS-Elements 
version 3.0, Nikon, Japan. 
2.3. Immunofluorescence- MV4-11 cells were cytospun onto glass slides at 500 rpm for 2 mins. Cells 
were fixed for 10mins using 4% PFA/PBS and permeabilized with 0.2% Triton-X-100 for 5 mins at 
room temperature.  Following washes, the cells were incubated with 50 µl of appropriate primary 
antibody diluted in 5% FBS/PBS for 1 hour at room temperature in a humidity chamber. Following 
washes, secondary antibodies conjugated to Alexafluor488 or 594 diluted in 5% FBS/PBS were added 
for 1 hour in the dark. Slides were washed and mounted using Mowiol. Secondary antibody only 
controls were used. 
2.4. Labelling of the plasma membrane FLT3-ITD– Live cell immunofluorescence of the plasma 
membrane FLT3-ITD of MV4-11 cells was performed on ice. Following centrifugation at 1,000 rpm 
for 5 mins, cells were incubated with anti-FLT3 primary antibody diluted in 5% FBS/PBS containing 
~0.01% Sodium Azide for 1 hour. Following washes, the cells were incubated with anti-rabbit 
Alexafluor488 diluted in 5% FBS/PBS for 1 hour. Secondary antibody only controls were used. Cells 
were washed and viewed under the microscope in ice cold PBS and quantified by flow cytometry using 
FACSCalibur (BD Biosciences, Europe) and Cellquest Pro software (Becton Dickinson). The mean 
fluorescent intensity of 10,000 events was determined.  
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2.5.Measurement of intracellular H2O2- The measurement of intracellular H2O2 procedure was 
performed as previously described in (18). Briefly, following treatments, total intracellular H2O2 was 
measured by incubating cells with 5 µM of cell-permeable H2O2-probe PO1 (Tocris) for 1 hour at 37°C 
in the dark. Cells were viewed under the microscope and quantified by flow cytometry using 
FACSCalibur (BD Biosciences, Europe) and Cellquest Pro software (Becton Dickinson). The mean 
fluorescent intensity of 10,000 events was determined. 
2.6. Western Blotting- The immunoblotting procedure was carried out as previously described (17). 
Briefly, the cells were lysed in RIPA buffer [Tris–HCl (50mM; pH 7.4), 1% NP-40, 0.25% sodium 
deoxycholate, NaCl (150mM), EGTA (1mM), sodium orthovanadate (1mM), sodium fluoride (1mM), 
cocktail protease inhibitors (Roche, Welwyn, Hertforshire, UK) and phenylmethanesulfonyl fluoride 
(1mM)] for 35-45 minutes on ice, followed by centrifugation at 14,000 rpm for 15 mins. The protein 
concentration was determined using the Bio-Rad Protein Assay (Bio-Rad, Hemel Hempstead, UK). 
Equivalent amounts of protein were resolved using SDS-PAGE followed by transfer to nitrocellulose 
membrane and incubated overnight with primary antibodies. The membrane was incubated in secondary 
antibody coupled with Alexa Fluor 680 or 800. The signal was detected with an Odyssey infrared 
imaging system (LI-COR Biosciences). 
Statistical Analysis- The results are expressed as a percentage of control, set to 100%. Values are 
representative of mean ± SD and are representative of three independent experiments. Statistical 
significance was analyzed by Student’s t test with p<0.05 representing a significant result. 
 
3. Results 
3.1. Receptor trafficking inhibitors, Tunicamycin and Brefeldin A, induce ER retention of FLT3-ITD. 
MV4-11 cell line is a well-established model of AML that expresses homozygous FLT3-ITD. FLT3-
ITD is the most prevalent FLT3 mutation resulting in ligand-independent constitutive activation of the 
receptor at the plasma membrane and impaired trafficking of the receptor in intracellular compartments, 
such as the ER. Cells were treated with Tunicamycin and Brefeldin A to inhibit glycosylation of FLT3-
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ITD resulting in impaired trafficking of FLT3-ITD receptor to the plasma membrane. Tunicamycin 
prevents glycosylation of plasma membrane receptor, retaining receptors in intracellular compartments 
by blocking the formation of protein N-glycosidic linkages and consequently blocking the first step of 
glycoprotein synthesis (28, 29). Brefeldin A inhibits mature and complex glycosylation of plasma 
membrane receptors through inhibition of guanine-nucleotide exchange factors that are required for 
ADP-ribosylation factor (ARF) GTPases, which results in disruption of the structure and function of 
the Golgi apparatus (30). We show that treatment of MV-411 cells with Tunicamycin and Brefeldin A 
result in retention of FLT3-ITD in a compartment of the biosynthetic pathway such as the ER (KDEL; 
Figure1A-C).  We demonstrated that both of these treatments resulted in a decrease of 50-60% of FLT3-
ITD expression at the plasma membrane when compared to vehicle control (Tunicamycin; DMSO and 
Brefeldin A; Ethanol) as quantified by flow cytometry (Figure 1D-H).  
 
3.2. Impaired trafficking of FLT3-ITD receptor to the plasma membrane results in a decrease in protein 
expression of NOX4 and its partner protein p22phox. 
FLT3-ITD expressing cell lines have been shown to express higher levels of endogenous ROS in 
comparison to FLT3-WT receptor cell lines (15, 18). The mechanism in which FLT3-ITD driven pro-
survival ROS leads to the aggressive form of AML remains unknown. We examined the effect of ER 
retention of FLT3-ITD on protein expression of p22phox and NOX4. p22phox and NOX4 protein 
expression decreased significantly following treatment with both receptor trafficking inhibitors, 
Tunicamycin and Brefeldin A (Figure2A and B). This suggests that for FLT3-ITD to produce NOX-
generated pro-survival ROS it has to be located at the plasma membrane. This is supported by previous 
work from our laboratory showing that ligand-stimulated FLT3-WT results in an increase in p22phox 
expression (18). 
 
3.3. NOX-generated ROS contribute to total pro-survival ROS in AML. 
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Our group has shown previously in that knocking down p22phox resulted in almost 20% decrease in total 
and nuclear H2O2 and knocking down NOX4 resulted in approximately 30% decrease of total cellular 
H2O2 and 20% decrease of nuclear H2O2 (18). Given that ER retention of FLT3-ITD resulted in a 
substantial loss of p22phox and NOX4 protein expression we decided to investigate the effect of ER 
retention of FLT3-ITD on total endogenous H2O2 using the probe Peroxy Orange 1 (PO1). This revealed 
that Tunicamycin treated cells resulted in approximately 35% decrease and Brefeldin A treated cells 
resulted in approximately 25% decrease of total endogenous H2O2 as quantified by flow cytometry. 
(Figure 3A-D) 
 
3.4. Mitochondrial-generated ROS contribute to total endogenous H2O2 in AML. Cyclooxygenase-
generated ROS do not contribute to endogenous H2O2 in AML. 
p22phox and NOX4 contribute to approximately 25-35% total endogenous H2O2 (Figure 3C and D). We 
investigated other potential sources of ROS that may contribute to total endogenous H2O2 in FLT3-ITD 
expressing AML. We used cyclooxygenase inhibitor, Diclofenac and mitochondrial ROS inhibitor, 
Rotenone and measured their effect on total endogenous H2O2 using PO1. Quantification by flow 
cytometry revealed that cyclooxygenase-generated ROS do not contribute significantly to total 
endogenous H2O2. However, inhibition of mitochondrial-generated ROS using Rotenone at high 
concentrations resulted in approximately 30% decrease of total endogenous H2O2. (Figure 3E and F)  
 
3.5. FLT3-ITD at the plasma membrane is responsible for the activation of AKT and GSK3β pro-
survival pathways. 
Constitutive activation of FLT3 switches on downstream signaling pathways such as PI3K, MAPK, 
ERK and STAT5. We investigated the outcome of treating MV4-11 cells with Tunicamycin and 
Brefeldin A on AKT and GSK3β pro-survival pathways. Impaired trafficking of FLT3-ITD receptor at 
the plasma resulting in ER retention of FLT3-ITD revealed a decrease in pAKT and pGSK3β (Figure 
4A and B). Thus, AKT and GSK3β cell signaling pathways are activated downstream of FLT3-ITD at 
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the plasma membrane. A decrease in total AKT was observed following treatment with the receptor 
trafficking inhibitors. 
 
3.6. AKT pathway needs to be activated in order for FLT3-ITD at the plasma membrane to produce its 
oncogenic effects. 
Given that both AKT and GSK3β are switched on downstream of ligand-independent constitutively 
activated FLT3-ITD receptor we investigated which signaling pathways are responsible for the aberrant 
production of NOX4-generated pro-survival ROS. Inhibition of AKT pathway using the inhibitor 
LY294002 (LY) resulted in a decrease in p22phox and NOX4 protein expression, whereas inhibition of 
GSK3β using the inhibitor SB216763 (SB) showed no effect on the protein expression of NOX4 and 
p22phox (Figure 4C). Thus, the AKT pathway needs to be phosphorylated and activated in order for 
FLT3-ITD at the plasma membrane to produce is oncogenic effects. The decrease in total AKT 
expression is result of AKT being hyper-phosphorylated leading to the aberrant signaling of FLT3-ITD. 
Inhibition of FLT3-ITD using PKC412, a drug in clinical trial to treat AML (31), resulted in a decrease 
in protein expression of p22phox, NOX4, pAKT and pGSK3β as expected (Figure 4D). 
 
3.7. Inhibition of FLT3-ITD cell surface expression results in proteasomal degradation of p22phox and 
deglycosylation of NOX4. 
Our group has shown that inhibition of FLT3-ITD using PKC412 results in proteasomal degradation of 
p22phox by the ubiquitin proteasome pathway (17). Given that p22phox and NOX4 protein expression 
decreases significantly following treatment with Tunicamycin and Brefeldin A, we decided to 
investigate whether impaired trafficking of FLT3-ITD resulted in post-transcriptional regulation of 
p22phox and NOX4. To this end, we treated cells with Tunicamycin and Brefeldin A in the presence of 
20S proteasome inhibitor, Lactacystin. ER retention of FLT3-ITD resulted in NOX4 deglycosylation 
and p22phox degradation by the proteasome. Inhibition of the 20S proteasome resulted in recovery of 
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p22phox protein expression (Figure 5A and B). Interestingly, this increase in p22phox protein expression 
to basal level did not coincide with an increase in endogenous H2O2 (Figure 5C and D). 
 
4. Discussion 
Oncogenic kinases act as drivers of ROS production in myeloid leukemia (32). Mutations in tyrosine 
kinases are commonly found in cancer and act as  primary or secondary mediator of oncogenic 
signalling (1). FLT3-ITD is the most prevalent FLT3 mutation expressed in 20% of AML cases. 
Constitutive activation of FLT3-ITD at the plasma membrane and ER is associated with poor prognosis 
(33). A number of studies have investigated the function of ROS, specifically NOX4-generated ROS in 
AML. Our group has shown that NADPH oxidases (NOX), in particular NOX4 and p22phox, a small 
membrane subunit of the NOX complex, are major sources of ROS in AML (17, 18). However, the 
molecular mechanism describing how mislocalized activation of FLT3-ITD and the aberrant signaling 
of downstream pathways (PI3K/AKT, ERK/MAPK and STAT5) leads to the production of ROS 
remains unknown.  
NOX-derived ROS have been shown to have numerous effects in leukemia including differentiation 
block, cell proliferation and resistance to apoptosis (34, 35). Leukemic oncogenes have been widely 
documented in the regulation of the expression of the NOX family and their partner protein, p22phox (22, 
34, 36, 37). p22phox is a membrane-bound protein and is an essential component required for fully 
functioning NOX1-4 (21). Our group demonstrated that cells expressing FLT3-ITD produce higher 
levels of pro-survival reactive oxygen species (ROS) in comparison to FLT3-wild type (18). 
In this study, we investigated the role of trafficking of the oncogenic FLT3-ITD receptor and its effect 
on the production of ROS utilizing receptor trafficking inhibitors, Tunicamycin and Brefeldin A. We 
found that Tunicamycin and Brefeldin A cause ER retention of FLT3-ITD (Figure 1) by inhibiting the 
glycosylation of FLT3-ITD receptor (27). p22phox and NOX4 protein expression decrease significantly 
following ER retention of FLT3-ITD (Figure 2) suggesting that p22phox and NOX4 protein expression 
and activation is dependent on FLT3-ITD being present at the plasma membrane. Importantly, to our 
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knowledge, this is the first study that finds FLT3-ITD cellular organization to play an essential role in 
the production of NOX4-generated pro-survival ROS and p22phox stability.  
Our group has shown that inhibition of FLT3-ITD results in post-translational regulation of p22phox (17). 
Here, we show that a decrease in p22phox and NOX4 protein expression following ER retention of FLT3-
ITD correlates with a decrease in endogenous H2O2 (Figure 3). Thisdata suggests that p22phox- and 
NOX4-generated H2O2 contribute to total endogenous H2O2 in FLT3-ITD AML. Also we found that 
mitochondrial-generated ROS contribute to endogenous H2O2 in FLT3-ITD expressing AML (Figure 
3). Interestingly, we have shown that cyclooxygenase-generated ROS do not contribute to total pro-
survival ROS in FLT3-ITD expressing AML (Figure 3). 
Three major survival signaling pathways activated downstream of FLT3-ITD are PI3K/AKT, 
Raf/MEK/ERK1/2 and STAT5 pathways. In this study, we looked at the effect of ER retention of FLT3-
ITD on PI3K/AKT and ERK pathways. As shown, both pathways are activated downstream of FLT3-
ITD at the plasma membrane (Figure 4). Inhibition of both of these signaling pathways revealed that 
the PI3K/AKT pathway is responsible for the activation and generation of NOX4-generated ROS 
(Figure 4). Although ERK pathway is located downstream of FLT3-ITD, it has minimal effect on 
p22phox and NOX4 expression (Figure 4). This result demonstrated that AKT regulates p22phox and 
NOX4 expression and is responsible for the production of pro-survival ROS in FLT3-ITD expressing 
AML. 
Tunicamycin and Brefeldin A inhibit glycosylation of many proteins. For this reason they are not 
suitable for the treatment of FLT3-ITD expressing AML cases. They have however previously been 
used to examine the effects of cellular localization of oncogenic FLT3-ITD and its effect on pro-survival 
signaling pathways (27). In this study, a mutant of FLT3-ITD was created that contained a deletion of 
the extracellular ligand-binding domain of FLT3-ITD (FLT3-ITD ΔECD). This mutation eliminated 
many potential sites of glycosylation, resulting in glycosylation-independent trafficking of the FLT3-
ITD receptor. Inhibition of FLT3-ITD ΔECD with PKC412 resulted in a loss of pro-survival signaling, 
as indicated by a decrease in pERK1/2 and pAKT. Due to the mutation in glycosylation sites recognized 
by Tunicamycin, treatment with this inhibitor had no effect on trafficking of the receptor and pERK1/2 
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and pAKT levels remained high. Brefeldin A inhibits glycosylation of receptors indirectly by disruption 
of the structure and function of the Golgi apparatus. Treatment with Brefeldin A therefore successfully 
inhibited trafficking of the receptor to the plasma membrane and as a result, pERK1/2 and pAKT levels 
decreased. As further support, they showed that wild-type FLT3, found only at the plasma membrane, 
in the presence of FLT3 ligand leads to the activation of PI3K and ERK signaling (27). These findings 
not only support the current study, highlighting a crucial role for FLT3-ITD at the plasma membrane in 
stimulating pro-survival signaling, but it also endorses the use of inhibitors, such as Tunicamycin and 
Brefeldin A, as a method to investigate the effect of subcellular localization of FLT3-ITD on the 
production of pro-survival ROS. 
We have demonstrated that ER retention of FLT3-ITD results in proteasomal degradation of p22phox 
(Figure 5). Receptor trafficking inhibitors, Tunicamycin and Brefeldin A inhibit glycosylation. NOX4 
is glycosylated at two positions, amino acid position 133 and 230 (38). Treatment of FLT3-ITD AML 
expressing cells with these inhibitors results in deglycosylation of NOX4. p22phox protein expression 
was recovered following treatment with the 20S proteasome inhibitor Lactacystin (Figure 5). 
Interestingly, p22phox function was not recovered, as observed by no significant increase in endogenous 
H2O2. 
In conclusion, we propose that FLT3-ITD at the plasma membrane is responsible for the activation and 
expression of p22phox- and NOX4-generated pro-survival ROS in FLT3-ITD expressing AML cells in 
(Figure 6). p22phox is essential for the maintenance of pro-survival signaling in AML. For FLT3-ITD to 
generate its oncogenic effects it has to be located at the plasma membrane. ER retention of FLT3-ITD 
results in NOX4 deglycosylation and p22phox proteasomal degradation. This study presents FLT3-ITD 
at the plasma membrane as a potential therapeutic target, in preventing downstream ROS-driven 
oncogenic effects. 
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2 column figure 
Figure 1. Tunicamycin and Brefeldin A induce ER retention of FLT3-ITD. (A-C) Colocalization 
of FLT3 with ER marker KDEL in MV4-11 cell line. Untreated (A), Tunicamycin treated (5µg/ml 
overnight) (B) and Brefeldin A treated (10µg/ml overnight) (C). Scale bar represents 30µm. (D-F) Live 
cell immunofluorescence of FLT3 at the plasma membrane in MV4-11 cell line, Untreated (D), 
Tunicamycin treated (E) and Brefeldin A treated (F). Scale bar represents 30µm. (G and H) Flow 
cytometric analysis of mean relative FLT3 fluorescence at the plasma membrane in MV4-11 cell line 
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treated with Tunicamycin (G) and Brefeldin A (H). Bar charts show relative mean FLT3 fluorescence 
of treated cells expressed as % of control. Results are representative of three independent experiments. 
Asterisks indicate statistically significant difference (****; p<0.0001) as analyzed by Student t-test. 
Error bars represent ± SD. 
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1 column figure 
Figure 2. Plasma membrane FLT3-ITD stabilizes p22phox and NOX4 expression at the protein 
level. (A and B) Western Blot analysis of p22phox and NOX4 protein expression in untreated (UT), 
vehicle control (control) and following treatment with Tunicamycin (5 µg/ml) overnight (A) and 
Brefeldin A (10 µg/ml) overnight (B). β-Actin was used as a loading control. 
19 
 
 
2 column figure 
Figure 3. NOX and mitochondrial-generated ROS contribute to total endogenous H2O2 in FLT3-
ITD expressing cells. (A and B) Live cell immunofluorescence of total cellular H2O2 levels in vehicle 
control (control) and Tunicamycin treated (5 µg/ml overnight) (A) and Brefeldin A treated (10 µg/ml 
overnight) (B) treated MV4-11 cells as measured by H2O2-probe, Peroxy Orange 1 (PO1). Scale bar 
represents 30µm. (C-F) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cell 
line treated with Tunicamycin (C), Brefeldin A (D), Diclofenac for 2 hours at indicated concentrations 
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(E) and Rotenone for 1 hour at indicated concentrations (F). Bar charts show relative mean PO1 
fluorescence of treated cells expressed as % of control. Results are representative of three independent 
experiments. Asterisks indicate statistically significant difference (**; p<0.01) and (****; p<0.0001) as 
analyzed by Student t-test. Error bars represent ± SD. 
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2 column figure 
Figure 4. Tunicamycin and Brefeldin A inhibit FLT3-ITD-induced PI3K signaling. NOX4-
generated pro-survival ROS requires AKT activation. (A and B) Western blot analysis of AKT and 
GSK3β signaling in untreated (UT), vehicle control (control), and following treatment with 
Tunicamycin (5 µg/ml) overnight (A) and Brefeldin A (10 µg/ml) overnight (B). Western blot analysis 
of p22phox and NOX4 protein expression in MV4-11 cells following treatment with LY294002 (LY; 
50µM) and SB216763 (SB; 5µM) overnight (C). Western blot analysis of p22phox, NOX4, pAKT, AKT, 
pGSK3β and GSK3β protein expression in vehicle control (control) and PKC412 treated MV4-11 cells 
(D). β-Actin was used as a loading control. 
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1.5 column figure 
Figure 5. Tunicamycin and Brefeldin A induce ER retention of FLT3-ITD, resulting in NOX4 
deglycosylation and p22phox proteasomal degradation. (A and B) Western blot analysis of p22phox 
and NOX4 signaling in untreated (UT), vehicle control (control), and cells treated with Tunicamycin (5 
µg/ml) and Lactacystin (5 µM) overnight (A) and Brefeldin A (10 µg/ml) and Lactacystin (5 µM) 
overnight (B). β-Actin was used as a loading control. (C and D) Flow cytometric analysis of mean 
relative PO1 fluorescence in MV4-11 cell line treated with vehicle control (control), and cells treated 
with Tunicamycin (5 µg/ml) and Lactacystin (5 µM) overnight (C) and Brefeldin A (10 µg/ml) and 
Lactacystin (5 µM) overnight (D). Bar charts show relative mean PO1 fluorescence of treated cells 
expressed as % of control. Results are representative of three independent experiments. Asterisks 
indicate statistically significant differences (****; p<0.0001) as analyzed by Student t-test. Error bars 
represent ± SD. 
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1 column figure 
Figure 6. A schematic of proposed mechanism in which FLT3-ITD at the plasma membrane and 
its downstream pro-survival pathways leads to the production of NOX4 pro-survival ROS in 
FLT3-ITD AML cells. FLT3-ITD at the plasma membrane is responsible for activation and 
phosphorylation of AKT signalling pathway and the production of p22phox-generated H2O2. Inhibition 
of FLT3-ITD generated-ROS at the plasma membrane leads to NOX4 deglycosylation and p22phox 
proteasomal degradation. 
 
